209 related articles for article (PubMed ID: 23638727)
1. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin's contribution to the treatment of sarcomas.
Blay JY
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
8. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin therapy for sarcomas.
Casali PG; Sanfilippo R; D'Incalci M
Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
Bongiovanni A; Riva N; Ricci M; Mercatali L; Liverani C; La Manna F; De Vita A; Cavaliere D; Pieri F; Oboldi D; Verdecchia GM; Amadori D; Ibrahim T
BMC Cancer; 2015 Dec; 15():998. PubMed ID: 26695071
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
12. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
14. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
15. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
[TBL] [Abstract][Full Text] [Related]
17. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
19. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Ray-Coquard I
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
[TBL] [Abstract][Full Text] [Related]
20. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
